New Investment: Hilltop Bio
Regenerative therapeutics is one of the most exciting and fast moving arenas in biotech. The expansion of these techniques into veterinary medicine isn’t just good for the animals we love, it’s a massive economic opportunity.
Pleased to announce our follow-on investment investment into Hilltop Bio. Hilltop’s trajectory over the last few years has been incredible to watch and we’re thrilled to deepen our support.
Hilltop Bio now offers an array of developed regenerative therapies to help animals heal from injuries and disease. Its products support joint health, soft tissue repair, and ophthalmology, and they’re built on BioStabyl™, a proprietary process designed to keep the healing components in biological material intact. Where steroids and NSAIDs manage symptoms, regenerative biologics work with the body’s own ability to heal.
The company began when founder and CEO Amanda Drobnis, a lifelong equestrian, suffered a serious hip injury at 29 and her doctors gave her two options: a full hip replacement or an experimental regenerative treatment. She chose to experiment. Within weeks, she was back on her feet and back in the saddle. After experiencing the benefits of regenerative therapy herself, Amanda went on to build Hilltop to bring that same technology to animals.
Today, veterinarians in clinics across the U.S. use Hilltop’s shelf stable products, from general practitioners to board-certified specialists in surgery, sports medicine, and rehabilitation. The company serves equine and canine patients, from elite athletes to family pets, and sells through national veterinary distributors.
And Hilltop gives back, donating $1 to Not One More Vet for every unit sold.
Hat’s off to Amanda and her growing team at Hilltop. It’s been an honor to be a small part of their story and we’re excited for all that lies ahead!
———
More About RevUp Capital
RevUp Capital invests in B2B and B2C companies that are revenue-driven and ready to double down on growth. We deploy cash and capacity to help companies grow from $1-3M to $10-30M, quickly and efficiently, using a revenue-based model. Companies enter our portfolio with $500K-$3M in revenue, a strong growth rate, and a team that’s ready to scale. Our typical investment range is $300K-$500K.
More at www.revupfund.com
How We Invest
We built RevUp to invest into B2B and B2C companies ascending the $1M-$10M growth curve. We know from experience—and from the stellar performance of our portfolio—that this curve can be conquered. But, having the right resources and support along the way is critical to success.
RevUp combines non-dilutive investment with hands-on support to help companies build stronger, more scalable infrastructure for growth. And, we do it using a non-dilutive model. Our goal? Give companies the best shot at success while preserving founder equity, optionality, and autonomy.
For more info visit here.